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Existing therapies such as irradiation or sorafenib have limited success in the treatment of hepatocellular car-
cinoma (HCC) due to tumor recurrence and metastasis. Therefore, combination with other therapeutics is
often considered. Macrophage inflammatory protein-1 alpha (MIP-1α) is a member of a family of chemo-
attractant cytokines that can induce the migration of monocytes, which in turn can play a role in fighting
tumors. This study investigated whether intravenous injection of MIP-1α in conjunction with irradiation or
sorafenib could enhance the antitumor effects on murine hepatoma. An HCa-I tumor was grown on the right
thigh of each C3H/HeN mouse. Mice were then treated with 10 Gy of irradiation, sorafenib, or a combination
of MIP-1α with either irradiation or sorafenib, and antitumor and antimetastatic effects were then investigated.
To understand the mechanisms, changes in the level of immunological markers were also evaluated.
Combination treatment of MIP-1α with irradiation or sorafenib resulted in a significant enhancement of antitu-
mor effects, prevention of lung metastasis and increase in host survival. This was achieved by significantly
increasing the levels of the immunological markers: Cluster Differentiation (CD) 8, CD107A and CD11C.
We conclude that a combination treatment of MIP-1α with irradiation or sorafenib would be a useful strategy
for management of hepatoma.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and seventh in women worldwide, and the
global incidence of this malignancy is rising [1]. HCC is a
devastating tumor that has a survival rate of < 5% over a
5-year period as a result of a high incidence of metastasis
and recurrence [2, 3]. Close attention to metastasis to other
organs is required in order to achieve effective HCC manage-
ment, and surgery, chemotherapy and irradiation are widely
used [4, 5]. However, the therapeutic outcome of these treat-
ments remains unsatisfactory. In particular, irradiation and
sorafenib, which are increasingly used in HCC, are not very
effective at preventing metastasis [6, 7].
Irradiation uses high-energy beams to destroy cancer cells
and is used as adjuvant therapy, either to prevent tumor
recurrence after surgery or to remove a primary tumor [8, 9].
However, irradiation has to be used carefully in the treatment
of HCC because liver tissues are highly susceptible to radi-
ation damage [10, 11]. Moreover, some metastatic HCC can
recur when cancer stem cells are resistant to irradiation.
Recent studies have shown a survival benefit from sorafenib,
making it the new standard therapy for patients with
advanced HCC [12]. However, the survival benefit is only a
few months. Additionally, many patients require dosage re-
duction or cessation of treatment because of adverse effects
of the drug [13]. A recent study has even indicated that treat-
ment with sorafenib contributes to increased invasiveness
and metastatic potential in orthotopic HCC models and cell
lines [14]. Therefore, combination treatments of existing
therapies with novel chemotherapeutics are being investi-
gated in an attempt to overcome these problems [15, 16].
Journal of Radiation Research, 2015, 56, 37–45
doi: 10.1093/jrr/rru077 Advance Access Publication 15 September 2014
© The Author 2014. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
Macrophage inflammatory protein-1 alpha (MIP-1α) is a
member of a family of chemotactic cytokines. MIP-1α have
been implicated in immune reactions. MIP-1α induces the
migration of T cells and monocytes, and the monocytes can
then differentiate into immune cells such as macrophages or
dendritic cells (DCs). Additionally, MIP-1α-recruited DCs
have therapeutic efficacy on metastatic tumors [17], and
fission yeast-generated MIP-1α, now known as ECI-301,
enhances the anti-tumor efficacy of irradiation via recruit-
ment of CD8-positive T cells and NK cells in lung and colon
cancers [18].
In this study, we investigated whether the combination of
recombinant MIP-1α with irradiation or sorafenib treatment
enhances antitumor effects and host survival in a system of
murine lung metastatic hepatoma.
MATERIALS ANDMETHODS
Animals and tumors
The animal facilities were approved by the Association of
Assessment and Accreditation of Laboratory Animal Care
(AAALAC), and all experiments were performed under the
institutional guidelines established by the Institutional
Animal Care and Use Committee at Yonsei University
(IACUC-2012-0177). Male C3H/HeN mice aged 6–7 weeks
old were purchased from Orient (Seong-nam, South Korea).
All mice were raised with free access to food and water
under specific pathogen-free conditions in a room main-
tained on a 12-h light/dark cycle. HCa-Ι is a murine hepa-
toma was used for tumor growth. Heterotopic tumor models
were generated by injecting 1 × 106/100 μl of tumor cells
into the right thigh.
Compounds
Sorafenib [N-(3-trifluoromethyl-4-chlorophenyl)-N’-(4-(2-
methylcarbamoyl pyridin-4-yl)oxyphenyl)urea] was synthe-
sized at Bayer Corporation (West Haven, CT, USA).
Sorafenib in 100% DMSO was mixed with an aqueous solu-
tion containing 8.75% ethanol and 12.5% Chremophor EL
(30 mg/kg, peroral, Sigma, St Louis, MO). Human recom-
binant MIP-1α was purchased from Sigma (St Louis, MO,
USA) and dissolved in phosphate-buffered saline (PBS,
2 μg/30 ml, intravenous), as described previously([19].
Irradiation
Tumor irradiation was accomplished by placing animals in
an acrylic chamber that immobilized the right leg without the
use of anesthesia. Lead shields were used to avoid irradiation
of other body parts. Tumors were irradiated with an X-ray
irradiator (X-RAD 320, Precision X-Ray) using 2.0-mm Al
filtration (300 kVp) at a dose of 10 Gy.
Hematoxylin and eosin (H & E) staining
The tumors were harvested after euthanasia of mice and
were fixed using a 4% paraformaldehyde solution. Histological
evaluation was conducted by means of H & E staining. All of
the stained tissue sections were analyzed using a virtual micro-
scope (Olympus BX51, Japan) and Olyvia® software.
Lung metastasis assays
Mouse lungs were harvested at 20 days after first irradiation.
All extractions were performed after euthanasia. Bouin’s solu-
tion was prepared using 75 ml saturated aqueous solution of
picric acid and 25 ml of 40% aqueous formalin (Sigma,
St Louis, MO). Lungs were fixed by submersion in Bouin’s so-
lution for 6 h, and fixed lungs were transferred to 70% ethanol.
The number and mean size of lung nodules were analyzed.
Immunofluorescence
Immunofluorescence was performed according to the previ-
ously published procedure [20]. Tumor tissues were col-
lected from mice under deep anesthesia with pentobarbital
(50 mg/kg, intraperitoneal, Sigma, St Louis, MO, USA).
Tumor samples were fixed in 10% formalin and embedded
in paraffin. The paraffin-embedded blocks were cut into
5-μm-thick sections. For immunofluorescent staining, depar-
affinized samples were blocked with 10% normal horse
serum for 1 h and then incubated with primary antibody
against CD11c (ArHm mAb CD11c, 1:100, Abcam, CA,
USA). Antigen retrieval was accomplished at 37°C by prote-
ase K solution. The samples were incubated with ArHm IgG
antibody (Abcam, CA, USA). These were biotinylated and
conjugated with streptavidin-HRP (DAKO code K0675;
DAKO Corp., Carpinteria, CA, USA). Sections were
incubated with anti-rabbit secondary biotinylated antibody
and visualized with streptavidin conjugated to Fluorescein
(460 nm) (Vector, Burlingame, CA, USA).
Western blot analysis
Tumor tissues were collected from mice under deep anesthe-
sia, as mentioned above. Tumor tissues were chopped into
4-mm2 samples, and biopsies were homogenized in tissue
protein lysis buffer (Pierce, Rockford, IL). Homogenates
were centrifuged (13 000 rpm, 5 min), and protein super-
natant was collected. Total protein concentration was deter-
mined using a BCA assay (Pierce, Rockford, IL). For
western blots, 20 μg/30 μl protein extracts were separated by
electrophoresis on 12% polyacrylamide gels and electro-
transferred to nitrocellulose membranes (GE Life sciences,
Pittsburgh, PA, USA). Membranes were blocked for 1 h in
5% skim milk at room temperature and incubated overnight
at 4°C with the antibodies: Cluster Differentiation (CD)
8 (27 kDa) or CD107a (43 kDa) (1:500, Bioss, Woburn,
MA). Membranes were washed three times with TBST and
incubated for 1 h at room temperature in 1:1000 diluted goat
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anti-rabbit IgG HRP conjugate (Bioss, Woburn, MA, USA).
After three washes, blots were developed using chemilumin-
escent peroxidase substrate (Sigma–Aldrich, St Louis, MO,
USA) and exposed using X-ray film and developer (Agfa,
Mortsel, Belgium). Computer-assisted analysis of the bands
was performed with the ImageJ program (National Institutes
of Health, USA).
Immunohistochemistry
We immunostained 5-µm sections of the tumor tissues embed-
ded in paraffin using the ABC technique (Vector Elite Kit,
Vector, Burlingame, CA). Sections were incubated over two
nights at 4°C with monoclonal mouse anti-CD8, CD107A and
proliferating cell nuclear antigen (PCNA) (1:1000, Chemicon,
CA) and rinsed with 0.05M phosphate buffer saline (PBS) and
3% NGS. Then, sections were incubated with the secondary
biotinylated antibody (1:200, Vector, Burlingame, CA) and
reacted with 0.5 mg/ml 3,3’-diaminobenzidine tetrahydro-
chloride (DAB, Vector, Burlingame, CA). The DAB reactions
showed under the light microscope, and the number of stained
cells was quantified by stereological analysis using Image-J
software (National Institutes of Health, USA).
Statistical analysis
All data are presented as mean ± standard error of the mean
(SEM). Statistical significance was analyzed using Student’s
t-test or the Mann–Whitney rank sum test, depending on the nor-
mality of the data. A difference of P < 0.05 was considered to be
statistically significant. All statistical analyses were carried out
using Sigma Stat (ver. 3.5, Systat Software Inc., Chicago, IL).
RESULTS
Existing therapies produce antitumor effects
in murine hepatoma but do not prevent lung
metastasis
Heterotopic hepatomas grew on the right thigh of each mouse,
and H & E staining indicated their malignancy (Fig. 1A). To
evaluate the in vivo anticancer effects of existing therapies, we
investigated tumor volume and host survival. The number of
lung nodules was determined in order to investigate metastatic
effects. Tumor volume was calculated as previously described
[18]. Tumor growth was significantly inhibited by irradiation
and also by sorafenib (Fig. 1B). However, lung nodules were
not reduced by the existing therapies. There was no significant
difference when compared with the tumor control group mice
(Fig. 1C). When all mice in the tumor control group had died,
30% of mice still survived in the irradiation treatment group
and 40% in the sorafenib treatment group (Fig. 1D).
Strategies for combining MIP-1α with existing
therapies to treat murine hepatoma
HCa-Ι cells (1 × 106/mouse) were injected into the right thigh
of each mouse, and each treatment was performed to 8-mm
size of HCa-Ι tumor (Fig. 2A and B). The tumor was irradiated
with 10 Gy in a single dose on the first day of the experiment
(Fig. 2A). Sorafenib was given perorally for 20 days from the
first day of the experiment (Fig. 2B). MIP-1α was intravenous-
ly injected between the first and fifth days of the experiment
(Fig. 2A and B). Tumor volume and survival rate were mea-
sured from the first day of the experiment until 3 days after all
mice in the tumor control group had died. The lungs of the
mice in each experimental group were harvested on experimen-
tal Day 30 for lung metastatic analysis (Fig. 2A and B).
Combination of MIP-1α with existing therapies
increased antitumor efficacy, decreased lung
metastasis and increased host survival
To assess the in vivo the antitumor effects of combination
treatments, we investigated tumor number and volume and
host survival. The number of lung nodules was determined in
order to investigate metastatic effects. Using a combination
treatment of sorafenib with MIP-1α (sorafenib +MIP-1α), the
tumor volume significantly decreased by ~35% compared
with the tumor control group. And there was no significant dif-
ference, compared with a single treatment with sorafenib
alone. The combination treatment of irradiation with MIP-1α
(irradiation +MIP-1α) significantly suppressed tumor growth
by ~56% compared with the tumor control group and by
~34% compared with a single treatment with irradiation alone.
(Fig. 3A). Lung nodules were also significantly reduced by
combination treatments. The number of lung nodules were
reduced in the (irradiation + MIP-1α) and in the (sorafenib + -
MIP-1α) groups by ~34% compared with the tumor control
group (Fig. 3D, left). The mean size of lung nodules also
decreased by ~55% in the (irradiation +MIP-1α) group and by
~43% in the (sorafenib + MIP-1α) group compared with the
tumor control group (Fig. 3D, right). All lung nodule data indi-
cated that combination treatment with MIP-1α produced a
better outcome compared with usage of the existing therapies
singly (Fig. 3D). When all mice in the tumor control were
dead, surviving mice remained in the combined treatment
groups. The final survival rate was 50% in the (sorafenib + -
MIP-1α) group, but the (irradiation +MIP-1α) group demon-
strated the greatest rate of survival at 70% (Fig. 3C).
Combination treatment of MIP-1α with existing
therapies increased dendritic cell infiltration
in tumor
To investigate the chemoattractant effects of MIP-1α, we
evaluated the infiltration of DCs into tumors by combination
of MIP-1α treatment with existing therapies. DCs were con-
firmed by immunofluorescence staining using the CD11C
marker (Fig. 4A). Quantitative analyses indicated that com-
bination of MIP-1α treatment with irradiation or sorafenib
significantly induced DC recruitment into tumors compared
with the tumor control or single treatment with irradiation or
sorafenib (Fig. 4B).
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Combination of MIP-1α treatment with existing
therapies increased CD8 and CD107A expression
in tumors
To investigate the relative mechanism for the infiltration of
DCs, western blot and immunohistochemical analyses were
performed to investigate the expression of CD8 and CD107A
in the tumor (Fig. 5). The single treatments with irradiation or
sorafenib did not change the levels of CD8 protein or positive
cells compared with the tumor control (Fig. 5A and B),
however they decreased CD107A expression compared with
the tumor control (Fig. 5C). The CD8 protein level and
CD8-positive cells were significantly increased ~2- and 3-fold
Fig. 1. Comparison of anti-tumor effects on murine hepatoma from irradiation or sorafenib. (A) Heterotopic growth
of murine hepatoma (left) and H&E staining of tumor sections (right, 5 μm). (B) Treatment effect of irradiation or
sorafenib on tumor growth. (C) Number of metastatic lung nodules visualized (left) and quantified (right graphs). (D)
Survival rate was analyzed by a log-rank test based on the Kaplan–Meier method. A single asterisk indicates P < 0.05
compared with the tumor control. Results are presented as mean ± S.E.M.
K.-Y. Jeong et al.40
after combination treatment of MIP-1α with irradiation or sora-
fenib compared with the tumor control (Fig. 5A and B). The
CD107A protein level and CD107-positive cells were signifi-
cantly increased ~2- and 3.5-fold after combination treatment
of MIP-1α with irradiation or sorafenib compared with the
tumor control (Fig. 5C and D).
DISCUSSION
Our results demonstrated that combination of MIP-1α treat-
ment with irradiation or sorafenib enhanced the antitumor
effects on murine hepatoma. Radiotherapy and chemother-
apy are considered as helpful methods for management of
human HCC [21, 22]. Irradiation is used treat a primary
tumor or to prevent tumor recurrence after surgery [8, 9],
while sorafenib has been widely recognized, among the
various anticancer drugs, as a suitable management drug for
HCC. Recent research has indicated the survival benefits of
sorafenib [12].
Many patients with HCC in an advanced stage have been
given radiation therapy [23]. It has been reported that some
metastatic HCC can occur when cancer stem cells are resist-
ant to irradiation [24, 25]. Sorafenib has been demonstrated
to suppress tumor cell proliferation and angiogenesis by
inhibiting serine/threonine kinases [26, 27]. However, sorafe-
nib also influences human peripheral blood T-cell in vitro.
Sorafenib brings down the immune response mediated by
T-cells in rodents [28, 29]. These recent results clearly indi-
cate that treatment with sorafenib contributes to increased
invasiveness and metastatic potential in orthotopic HCC
models and cell lines [14].
We investigated the disadvantages of existing therapies in
a model of murine heterotopic hepatoma. HCa-Ι has radiore-
sistant and lung metastatic features and was established from
murine hepatoma grown spontaneously in C3H/HeN mice
[30]. Although existing therapies suppress tumor growth and
increase the survival rate, they have limitations in the man-
agement of HCC. In particular, lung metastasis is not inhib-
ited by existing therapies, as indicated by our results.
MIP-1α is a chemokine in the CC subfamily of chemo-
kines with the ability to induce a number of types of hemato-
poietic cells, particularly in those involved in adaptive
immune responses such as macrophages, DCs and T lym-
phocytes [31]. In previous animal studies combining
irradiation treatment with a recombinant MIP-1α variant
(ECI301), antitumor effects on lung carcinoma (together
with systemic effects) were demonstrated [18]. We developed
these strategies using a combination treatment of MIP-1α
Fig. 2. Schematic representation of experimental scheme for the effect of combination treatment of MCP-1α with irradiation or
sorafenib on murine hepatoma. (A) Combination treatment of irradiation with MIP-1α. (B) Combination treatment of sorafenib
with MIP-1α.
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with either irradiation or sorafenib and demonstrated im-
provement over existing therapies and increase in the antitu-
mor effects in hepatoma.
Administration of MIP-1α effectively recruited DCs into
the peripheral blood, and these recruited DC were able to
generate sufficient cell numbers for the DC-based antitumor
effects. MIP-1α-recruited DC can be used for eliminating
tumors and preventing metastasis [17]. When DCs recognize
an antigen, they stimulate T-cell responses via their potent
antigen-presenting capacity [32].
Solid tumors are thought to contain cancer stem cells
(CSCs) as a distinct population, and it is believed that these
are responsible for tumor relapse and metastasis as a conse-
quence of their abilities to self-renew, differentiate, and give
rise to a new tumor in local or distant organs. CSCs have
been identified in many tumor types, including HCC [33].
CSCs can escape the toxic effects of chemotherapy through
an assortment of mechanisms. There are a number of signal-
ing pathways that have been demonstrated to contribute to
chemoresistance, such as the notch signaling pathway [34].
Fig. 3. Comparison of antitumor effects on murine hepatoma from combination treatment of MCP-1α with irradiation or sorafenib. (A)
Effect of combination treatment of MIP-1α with irradiation or sorafenib on tumor growth. (B) Visualization of metastatic lung nodules after
combination treatments. (C) Survival rate was analyzed by a log-rank test based on the Kaplan–Meier method. A single asterisk indicates
P < 0.05 compared with the tumor control; two asterisks indicate P < 0.01 comparing the tumor control group with the (sorafenib +MIP-1α)
group. (D) The number (left graph) and mean size (right graph) of lung nodules were quantified. A single asterisk indicates P < 0.01
compared with the tumor control and the irradiation groups; hash indicates P < 0.01 compared with the tumor control and the sorafenib
groups. Results are presented as mean ± S.E.M.
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Based on findings that cancer cell clonogens exhibit stem
cell features, it has been suggested that cancer stem-like
cells are relatively radioresistant owing to a range of intrinsic
and extrinsic factors, including enhanced DNA repair, or
hypoxia and interaction with stromal elements [35]. Since
DNA polymerase epsilon is involved in the resynthesis of
excised damaged DNA strands during DNA repair, PCNA is
important for both DNA synthesis and DNA repair. The
combination treatments significantly decreased PCNA ex-
pression in the primary tumor (Supplementary Fig. 1). In
addition, the increase in MIP-1α-recruited DCs could have a
major role in triggering tumor-specific T-cell responses [17].
It is widely known that CD8-positive cytotoxic T-cells rec-
ognize and kill stem-like cells [36].
In our results, the combination of MIP-1α treatment with
existing therapies significantly inhibited lung metastasis. The
antitumor effect and host survival were also enhanced. We
have reasserted that infiltration of DCs into the tumor is
increased by MIP-1α. CD107a is a vesicle membrane protein
that becomes transiently mobilized to the cell surface during
this degranulation [37]. Confirmation of CD107a expression
is utilized to distinguish and isolate functional tumor-reactive
T-cellular telephones with high recognition efficiency direct-
ly of peripheral blood mononuclear cells of cancer patients.
The expression of CD107a can be applied to isolate tumor-
cytolytic T cells. CD107a moblization correlates well with
the cytotoxic activity of CD8-positive T cells [38]. The ex-
pression of CD107a rather decreased in the tumor after single
treatment with existing therapies, however CD107a signifi-
cantly increased in the tumor after the combination of MIP-1α
treatment with existing therapies. Activation of CD8-positive
T lymphocytes stimulated by MIP-1α-recruited DCs would
enable efficient recognition of stem-like cancer cells [39].
In conclusion, we demonstrated that the combination
of MIP-1α treatment with existing therapies (such as irradi-
ation or sorafenib) for hepatoma enhanced antitumor activity,
particularly the inhibition of lung metastasis. These effects
were brought about by cytotoxic CD8-positive T-cell
Fig. 4. Comparison of dendritic cell infiltration into tumors. (A) Images at × 400 magnification. Square box in images indicates merged
site. Scale bars, 20 μm. (B) Quantification analyses of CD11C expression. Single asterisk indicates P < 0.01 compared with the tumor control
and the irradiation groups; hash indicates P < 0.01 compared with the tumor control and the sorafenib groups. Results are presented as
mean ± S.E.M.
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activation resulting from the interaction of T-cells with DCs
recruited by MIP-1α. Therefore, our findings indicate that
the combination of MIP-1α treatment with existing therapies
is a potential strategy for treating metastatic hepatoma.
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Supplementary data are available at the Journal of Radiation
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